Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04884282
Title	Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (COMBI-TED)
Acronym	COMBI-TED
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Fondazione Ricerca Traslazionale
Indications	lung non-small cell carcinoma
Therapies	Docetaxel + OSE 2101 Docetaxel Nivolumab + OSE 2101
Age Groups:	adult \| senior
Covered Countries	ITA \| FRA \| ESP